Takeda Pharmaceutical Company Limited SEC filings document its reporting as a foreign private issuer and ADR-listed pharmaceutical company that furnishes Form 6-K current reports and files annual reports on Form 20-F. The filings include English-language earnings reports, financial appendices, press releases and governance notices.
Takeda’s regulatory disclosures cover IFRS consolidated results, outlook commentary, ADR and foreign-issuer reporting status, board and representative-director matters, corporate transformation initiatives, and clinical or regulatory updates for programs such as zasocitinib, rusfertide and oveporexton. The filings also document pipeline-related financial-impact statements, shareholder meeting materials and formal exhibits furnished to the SEC.
Takeda Pharmaceutical Company Limited is launching the next phase of its global transformation program to boost competitiveness and support multiple upcoming drug launches. The company targets annualized gross savings of more than JPY 200 billion by FY2028, mainly through streamlined corporate functions, simpler processes and better use of technology.
These efficiencies are expected to largely offset investments in launch preparations for medicines such as oveporexton, rusfertide and zasocitinib, as well as late-stage pipeline and technology spending. Takeda currently estimates restructuring expenses of about JPY 150 billion in FY2026, with smaller charges in FY2027 and FY2028. The initiatives are not expected to have a significant impact on the full-year consolidated financial forecast for FY2025.
Takeda Pharmaceutical CEO-elect Julie So-Young Kim has filed an initial ownership report showing beneficial ownership of 324,729 American Depositary Shares. This total includes 150,956 restricted stock units (RSUs), each convertible into one ADS. The RSUs vest in stages: 70,110 on July 1, 2026, 52,218 on July 1, 2027, and 28,628 on July 1, 2028, highlighting a multi-year, equity-based incentive structure aligned with her leadership role.
TAKEDA PHARMACEUTICAL CO LTD Global General Counsel Natalie Anne Marie Furney filed an initial ownership report showing an award of 191,280 restricted stock units (RSUs), each representing a contingent right to receive one American Depositary Share.
The RSUs vest in three equal-time tranches: 63,758 on July 1, 2026, 63,758 on July 1, 2027 and 63,764 on July 1, 2028.
Takeda Pharmaceutical executive Teresa Marie Bitetti, President of the Oncology Business Unit, reports beneficial ownership of 193,148 American Depositary Shares. This total includes 85,802 restricted stock units, each convertible into one ADS.
The RSUs are scheduled to vest in three tranches: 40,056 shares on July 1, 2026, 30,564 shares on July 1, 2027, and 15,182 shares on July 1, 2028, providing a clearly defined equity vesting timeline.
Takeda Pharmaceutical filed an initial ownership report for Global Business Development Officer Marcello Pignagnoli Agosti. He reports direct ownership of 144,608 American Depositary Shares. This total includes 53,850 restricted stock units, each representing one ADS, vesting on July 1, 2026, July 1, 2027, and July 1, 2028 in scheduled installments.
Takeda Pharmaceutical director Yoshiaki Fujimori filed an initial ownership report listing his equity interests in the company. He directly holds 27,865 Ordinary Shares. The filing also notes 8,400 restricted stock units (RSUs), each representing a right to receive one Ordinary Share as they vest.
The RSUs vest on June 1, 2026 (2,100 shares), June 1, 2027 (2,200 shares), June 1, 2028 (2,100 shares) and upon retirement from board service (2,000 shares). Separate Tax Obligation Awards are described as economically equivalent to Ordinary Shares but payable in cash primarily to cover tax obligations at future vesting.
Takeda Pharmaceutical director Emiko Higashi filed an initial ownership report showing equity and award holdings in the company. The filing lists 7,600 American Depositary Shares and 17,800 Ordinary Shares held directly, plus restricted stock units and tax-related awards tied to future vesting.
Footnotes explain that 12,800 restricted stock units each convert into one Ordinary Share, then into American Depositary Shares, vesting on June 1, 2026, 2027, 2028 and upon conclusion of board service. Separate Tax Obligation Awards are each economically equivalent to one Ordinary Share and will be settled in cash at vest primarily to cover tax obligations.
TAKEDA PHARMACEUTICAL CO LTD executive Asuka Miyabashira, President of the Japan Pharma Business Unit, reports direct ownership of 3,000 Ordinary Shares. The position also includes 1,600 restricted stock units (RSUs), which are rights to receive one Ordinary Share each as they vest.
The RSUs vest in tranches of 700 shares on June 1, 2026, 500 shares on June 1, 2027, and 400 shares on June 1, 2028. In addition, Miyabashira holds Tax Obligation Awards that are economically equivalent to Ordinary Shares and are designed to be settled in cash primarily to cover tax obligations at the then-current market price when they vest.
Takeda Pharmaceutical Co. Ltd. executive Gabriele Ricci, Chief Data & Tech. Officer, reports beneficial ownership of 124,132 American Depositary Shares. This includes 45,774 restricted stock units, each representing a contingent right to one ADS, vesting on July 1, 2026 (21,952), July 1, 2027 (16,012) and July 1, 2028 (7,810).
Takeda Pharmaceutical Co. Ltd. director Kimberly A. Reed filed an initial beneficial ownership report showing a mix of share holdings and equity awards. She reports direct holdings of 9,700 Ordinary Shares and 8,975 American Depositary Shares. The filing also lists several Tax Obligation Awards, each economically equivalent to one Ordinary Share, covering 1,152, 1,192 and 1,180 underlying Ordinary Shares with vesting and expiration dates on June 1 of 2026, 2027 and 2028. Footnotes explain that separate restricted stock unit awards will vest in tranches of 3,100, 3,400 and 3,200 Ordinary Shares on those same dates, with each RSU converting into one Ordinary Share and then into an equivalent number of American Depositary Shares following vest.